Overview

Safety of Either a Single or Two IV Doses of Orbactiv in Subjects With ABSSSI

Status:
Completed
Trial end date:
2017-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of two 1200-mg IV infusions of oritavancin when administered one week apart.
Phase:
Phase 4
Details
Lead Sponsor:
The Medicines Company
Treatments:
Oritavancin